The cholesterol-dependent cytolysins (CDCs) are characterized by an undecapeptide sequence (ECTGLAWEWWR) that is located near the C terminus and within domain 4 of these proteins. Pyolysin (PLO), the CDC of Arcanobacterium pyogenes, has a variant undecapeptide sequence (EATGLAWDPWW). Site-directed mutants were constructed in undecapeptide residues in a recombinant PLO molecule containing a hexahistidine tag (His-PLO). Mutations in each of the three undecapeptide tryptophan residues resulted in low haemolytic activity, confirming the importance of these residues in the protein. Deletion of a proline residue (P 499 ), inserted in PLO, or substitution of this residue with either phenylalanine or glycine resulted in mutant proteins with undetectable or low haemolytic activities, indicating that P 499 is essential for His-PLO haemolytic activity. Substitution of the PLO undecapeptide sequence with a consensus undecapeptide resulted in a His-PLO protein with only 01 % activity, confirming that the variant PLO undecapeptide is required for the full cytolytic activity of this toxin. The presence of the conserved undecapeptide cysteine residue either alone (His-PLO.C 492 ) or in a consensus sequence resulted in His-PLO molecules which were activated in the presence of reducing compounds, confirming the importance of this residue in the thiol-activated nature of many CDC toxins. The ability of His-PLO mutant proteins to bind cholesterol mimicked haemolytic activity, with the exception of His-PLO.C 492 , which, despite having reduced haemolytic activity, showed an increased ability to bind cholesterol compared to His-PLO. Despite reductions in haemolytic activity and cholesterol-binding, all mutant proteins were still able to bind to erythrocyte membranes, suggesting that other regions of PLO may recognize host-cell membranes, through receptors other than cholesterol.
INTRODUCTION
Arcanobacterium pyogenes is commensal on the mucous membranes of the upper respiratory and urogenital tracts of cattle, sheep, swine and other domestic animals (Carter & Chengappa, 1991) . This organism is also commensal on the ruminal wall of cattle, from where it can participate in liver abscessation, secondary to ruminal acidosis (Narayanan at al., 1998) Abbreviations : BME, β-mercaptoethanol; CDC, cholesterol-dependent cytolysin ; ILY, intermedilysin ; LLO, listeriolysin O ; PFO, perfringolysin O ; PLO, pyolysin ; PLY, pneumolysin ; SRBC, sheep red blood cell. (Jost et al., 2002) suggests that it may also be a common inhabitant of the gastrointestinal tract of domestic animals. A. pyogenes is an important opportunistic pathogen of livestock and wild ungulates, causing diseases ranging from liver abscessation and mastitis in cattle (Jonsson et al., 1991 ; Lechtenberg et al., 1988 ; Nagaraja et al., 1996) to intracranial abscessation in white-tailed deer (Baumann et al., 2001) .
A. pyogenes secretes a haemolytic exotoxin, pyolysin (PLO) (Billington et al., 1997 ; Ding & La$ mmler, 1996) , which is an important virulence factor, as a knockout mutation in the plo gene resulted in reduced virulence of the mutant in a mouse model (Jost et al., 1999) . Recombinant PLO is also an effective vaccine in the prevention of experimental infections in mice (Jost et al., 1999) , although its ability to protect domestic animals from natural infection is still to be tested. PLO is a novel member of a group of toxins historically known as the thiol-activated cytolysins. As all members of this family are not subject to thiol-activation, including PLO (Billington et al., 1997 ; Nagamune et al., 1996) , a number of alternative designations have been proposed (Billington et al., 2000 ; Gilbert et al., 1999 ; Nagamune, 1997 ; Shatursky et al., 1999) , with cholesterol-dependent cytolysins (CDCs) (Shatursky et al., 1999) being the most widely accepted. This group of toxins, which includes listeriolysin O (LLO), perfringolysin O (PFO), pneumolysin (PLY) and streptolysin O, is characterized by an undecapeptide sequence (ECTGLA-WEWWR) located near the C terminus of the protein (Fig. 1a) . Oxidation of the cysteine residue within this sequence is responsible for the thiol-activated nature of many CDCs. Both PLO and intermedilysin (ILY) of Streptococcus intermedius have variant undecapeptide sequences, in which the conserved cysteine has been substituted with an alanine residue, resulting in oxygenresistant toxins (Billington et al., 1997 ; Nagamune et al., 1996 ; Nagamune, 1997) (Fig. 1a) . Many advances have been made in recent years as to the function of the four domains within the CDC tertiary structures and their roles in pore-formation (Tweten et al., 2001) . However, while it has been evident for some time that the undecapeptide is critical for CDC activity (Boulnois et al., 1991 ; de los Toyos et al., 1996 ; Jacobs et al., 1999 ; Korchev et al., 1998 ; Michel et al., 1990 ; Pinkney et al., 1989 ; Saunders et al., 1989 ; Sekino-Suzuki et al., 1996) , the precise function of this region of the molecule is unclear.
The crystal structure of the prototype CDC, Clostridium perfringens PFO, has been described as an elongated molecule composed of four β-sheet-rich domains, only one of which, the C-terminal domain 4, is contiguous within the primary amino acid sequence (Rossjohn et al., 1997) . A proposed structure for S. pneumoniae PLY based on a homology model with PFO indicates that PLY takes on a very similar structure ) and it appears likely, given the conservation of residues that map to the hydrophobic core of PFO, that all CDCs, including PLO, share a similar three-dimensional structure (Rossjohn et al., 1997) . Studies of pore formation by PFO (Heuck et al., 2000 ; Shatursky et al., 1999 ; Shepard et al., 1998 Shepard et al., , 2000 indicate that two transmembrane amphipathic β-hairpins (TMHs) from domain 3 span the membrane bilayer and serve as the membrane-aqueous interface of the PFO pore. In the crystal structure of the PFO monomer, the tryptophanrich undecapeptide region forms a hydrophobic loop at one end of domain 4 (Rossjohn et al., 1997) , initially proposed to extend out, as a result of cholesterol binding, to form a dagger which facilitates membrane insertion (Rossjohn et al., 1997) . However, it has recently been demonstrated that domain 4 does not penetrate deeply into the lipid bilayer, but is responsible for the initial interaction of CDCs with the host membrane (Heuck et al., 2000) . In fact, the conformational changes required to form the domain 3 TMHs do not take place until domain 4 has partially inserted into the lipid bilayer (Heuck et al., 2000) . Thus, domain 4 may act to sample the membrane for suitability or to tether monomers to the membrane in a pre-pore complex, prior to the insertion of the TMHs (Heuck et al., 2000 ; Hotze et al., 2002) . The undecapeptide sequence has been implicated in the initial binding of CDCs to host-cell membranes, as mAbs directed against the undecapeptide sequence block binding of PLY to erythrocyte membranes (Jacobs et al., 1999) , and sitedirected mutations in the undecapeptide sequences, particularly the conserved tryptophan residues, of many CDCs significantly affect the ability of these toxins to Mutagenesis of the undecapeptide sequence of pyolysin form pores (Boulnois et al., 1991 ; Michel et al., 1990 ; Sekino-Suzuki et al., 1996) . Both PLO and the human-specific cytolysin ILY have variant undecapeptide sequences (Billington et al., 1997 ; Nagamune, 1997) (Fig. 1a) . It is not known if this sequence divergence represents an attempt to regulate cytolytic activity or whether, in the case of PLO which is the most divergent member of the CDC family, the sequence divergence compensates for structural differences in other regions of the protein between PLO and the other CDCs. In this study, we examine the activity of various site-specific mutants in the undecapeptide of PLO and determine that the sequence variation in the PLO undecapeptide is required for full cytolytic activity.
METHODS
Bacterial strains and growth conditions. Escherichia coli strains DH5α and DH5αFhlacI q (Gibco-BRL) were grown either on Luria-Bertani (LB) agar or in LB broth (Difco) at 37 mC. Ampicillin (100 µg ml − ") was added to the medium when appropriate. DNA techniques. Procedures for E. coli transformation and plasmid extraction, DNA restriction, ligation, agarose gel electrophoresis and Southern blotting were performed as described by Ausubel et al. (1994) . Plasmids pJGS59, encoding a 543 aa protein (His-PLO) composed of 507 aa of the mature PLO with an N-terminal extension of 36 aa encoded by pTrcHis B, including a hexahistidine sequence, and pJGS89, a site-directed mutant of pJGS59 that encodes a mutant version of His-PLO with an alanine to cysteine change at position 492 (His-PLO.C %*# ), have been described previously (Billington et al., 1997) . pJGS59 and pJGS89 were used as templates for the construction of site-directed mutants, using the mutagenic primers indicated in Table 1 and the Transformer Site Directed Mutagenesis Kit (Clontech), according to the manufacturer's instructions. Two selection primers were used. Primer 5h-GACTTGGTTGAGGCCTCACCAGTCAC-3h was designed to change the ScaI site of pTrcHis B to StuI and was used in conjunction with forward primers listed in Table 1 . A second Table 1 . Construction of site-specific undecapeptide mutants in His-PLO
Toxin
Plasmid Mutagenic primer*
* Underlined sequences represent mutated codons. † The His-PLO undecapeptide sequence and its corresponding DNA sequence are shown.
selection primer, 5h-GAGTGCACCATGGGCGGTGTGA-AAT-3h, was designed to change the NdeI site of pTrcHis B to NcoI and was used in conjunction with the reverse primers listed in Table 1 . Introduction of appropriate mutations into either pJGS59 or pJGS89 was confirmed by automated DNA sequencing on a 373A DNA sequencer (Applied Biosystems) at the University of Arizona's DNA sequencing facility.
Production and purification of His-PLO and mutant proteins.
Cultures (500 ml) of E. coli DH5α or DH5αFhlacI q carrying pJGS59, or the appropriate site-directed mutant plasmid, were grown to an OD '!! value of 0n6 prior to induction with 2n5 mM IPTG for 3 h. Cells were harvested by centrifugation at 5000 g and the cell pellet was resuspended in binding buffer (20 mM Tris\HCl, 100 mM NaCl, pH 8n0). The cells were disrupted by two passages through a French Pressure Cell (Aminco) at 138 MPa and the insoluble material was removed by centrifugation at 12 000 g. His-PLO or mutant proteins were purified from the soluble fraction using TALON Metal Affinity Resin (Clontech) according to the manufacturer's instructions, and eluted from the column in binding buffer with 50 mM imidazole. Protein concentration was determined using the Bradford Protein Assay Reagent (Bio-Rad). Haemolytic assays. Microtitration haemolytic assays were performed essentially as described previously (Billington et al., 1997) , except that dilutions of toxins were performed in 1 mg BSA ml − " to aid in stabilization of the toxin. One haemolytic unit (HU) was defined as the amount of haemolysin (in ng) required to release 50 % of the haemoglobin from 200 µl of 0n25 % sheep red blood cells (SRBCs) in 1 h at 37 mC, and specific haemolytic activity was expressed as HU (µg protein) − ". The specific haemolytic activity of all His-PLO mutant proteins was expressed as a percentage of His-PLO haemolytic activity, which was designated as 100 %. The effects of reducing compounds on haemolytic activity was assayed by incubating 10 µg toxin preparations ml − " with final concentrations of either 2n5 mM DTT or 2 % (v\v) β-mercaptoethanol (BME) for 10 min at room temperature, prior to performance of the haemolytic assay. Cholesterol-binding assays. The relative cholesterol-binding affinity of His-PLO and mutant proteins was assayed by a modification of an ELISA technique developed by Shimada et al. (1999) . Microtitre plate wells were coated with 1 µmol of cholesterol, overnight at 37 mC. Following two washes in 0n1 M PBS (pH 7n2) containing 0n3% (v\v) Tween 20 (PBS-T), the wells were blocked for 1 h with 3 % (w\v) BSA in PBS at 4 mC. The wells were washed twice with PBS-T and incubated for 1 h at 37 mC with dilutions of toxin in 1 mg BSA ml − " (1 µg to 1 ng toxin or, where necessary, 10 µg to 10 ng toxin). Following nine washes with PBS-T, bound toxin was reacted with a 1\500 dilution of polyclonal goat anti-PLO serum (Billington et al., 1997) at 37 mC for 1 h. Primary antibody was detected using a horseradish-peroxidase-conjugated rabbitanti-goat IgG (HjL) peroxidase (KPL) and o-phenylenediamine as substrate (Sigma).
The cholesterol-binding activity was calculated as the amount of haemolysin (in ng) required to give an ELISA OD %#! value 50 % that given by 1 µg His-PLO. The binding activity of all His-PLO mutant proteins was expressed as a percentage of His-PLO binding activity, which was designated as 100 %. An ELISA was also performed on known amounts of each mutant toxin to confirm that His-PLO and each mutant reacted equally with the anti-PLO serum.
Membrane-binding assays. These were performed essentially as described by de los Toyos et al. (1996) . His-PLO and mutant toxins were diluted in 1 mg BSA ml − " to a concentration of 2n5 µg ml − ". Toxin (0n5 ml) was added to an equal volume of 10 % SRBC and incubated on ice for 20 min. SRBCs were pelleted by centrifugation at 14 000 g for 5 min at 4 mC. Cell pellets were lysed by boiling in sample buffer and were then subjected to SDS-PAGE and Western blot analysis with the anti-PLO serum to detect bound toxin.
RESULTS

The tryptophan residues of PLO are important in cytolytic activity
Mutations in any of the hydrophobic tryptophan residues of the undecapeptide have significant effects on the pore-forming ability of LLO, PFO and PLY (Boulnois et al., 1991 ; Korchev et al., 1998 ; Michel et al., 1990 ; Sekino-Suzuki et al., 1996) . To determine if this was also true for PLO, each of the three tryptophan residues was changed individually to phenylalanine to create His-PLO.F %*( , His-PLO.F &!! and His-PLO.F &!" (Fig. 1b) . Haemolytic assays were performed on purified protein from each of these mutants (Table 2) . Like other CDCs, each mutant had significantly reduced haemolytic activity compared to wild-type His-PLO. The most severe reduction was observed with His-PLO.F %*( , with only 0n2 % of His-PLO activity. The haemolytic activity of this mutant protein is consistent with observations from other CDCs, which suggest that the first tryptophan residue of the undecapeptide is essential for cytolytic activity (Boulnois et al., 1991 ; Sekino-Suzuki et al., 1996) . The haemolytic activities of His-PLO.F &!! and His-PLO.F &!"
at 2n3 and 5n0 % of wild-type His-PLO activity, respectively, also suggest that these residues are important for PLO activity.
The proline residue in the PLO undecapeptide is essential for activity
The major structural and charge differences between the PLO undecapeptide and the consensus undecapeptide for the CDC family appear to be the insertion of a proline (P %** ), which increases the spacing between the three tryptophan residues, and the lack of the terminal arginine (Fig. 1a) . A mutant His-PLO protein was created in which the proline was deleted and the arginine inserted (His-PLO.∆P %** ΩR &!# ) (Fig. 1b) . This mutant protein showed only 2n5 % haemolytic activity compared to wild-type His-PLO (Table 2 ). To determine which of the two mutations was having the greatest effect on activity, the arginine insertion (His-PLO.ΩR &!#
) and proline deletion (His-PLO.∆P %** ) mutations were introduced independently into His-PLO (Fig. 1b) . The His-PLO.ΩR &!# mutant protein, while reduced in activity compared to His-PLO, still had significant haemolytic activity at 27n5 % of wild-type ( Table 2 ). The His-PLO.∆P %** protein, however, had no detectable haemolytic activity, even at toxin concentrations greater than 2 mg ml −" . Thus, the relative haemolytic activity of the protein was less than 0n003 % of wild-type His-PLO. These data suggest that P %** plays an essential role in the cytolytic activity of PLO. To confirm the importance of P %** , site-specific mutants were created where the proline was substituted with either phenylalanine (His-PLO.F %** ) or glycine (His-PLO.G %** ) (Fig. 1b) . His- , Not determined.
* All protein preparations were stored at 4 mC for 2 weeks, prior to performing haemolytic assays. † The haemolytic and cholesterol-binding activities are expressed as a percentage of His-PLO activity from an average of three experiments p1  from the mean. ‡ Proteins were pre-incubated with 2 % (v\v) BME for 10 min at room temperature, prior to performing haemolytic or cholesterol-binding assays. § Proteins were pre-incubated with 2n5 mM DTT for 10 min at room temperature, prior to performing haemolytic assays. PLO CON jBME ; 12, His-PLO.C 492 jBME ; 13, His-PLOjBME. The positions of molecular mass markers are shown in kDa on the left of the image ; the arrow on the right indicates the position of the wild-type and mutant His-PLO proteins.
PLO.F %** and His-PLO.G %** were also impaired for haemolytic activity, with relative haemolytic activities of 1n3 and 0n4 % of His-PLO haemolytic activity, respectively ( Table 2 ).
The variation in the PLO undecapeptide is required for full cytolytic activity
Since there are other changes in the PLO undecapeptide that may compensate for the proline and arginine changes, a consensus undecapeptide was introduced into His-PLO. This protein was constructed in two forms, one containing a purely consensus CDC undecapeptide, His-PLO CON , which includes the conserved cysteine residue and another, His-PLO CON+A , containing all the consensus residues but retaining the alanine of PLO at position 492 (Fig. 1b) . Purified His-PLO CON (Table 3) and His-PLO CON+A (Table 2) both had very low haemolytic activities of 0n1 %. This result confirmed that the substituted residues in the PLO undecapeptide were required for full cytolytic activity of this protein.
Since His-PLO CON contained the conserved cysteine residue responsible for the thiol-activation of many CDCs, haemolytic assays were performed with purified protein pre-treated with either DTT or BME. In the presence of these reducing agents, the haemolytic activity of His-PLO CON was increased, approximately 10-fold over no treatment, to 1n0-1n1 % of His-PLO activity (Table 3) . While this activity is still very low, it represents a significant increase in activity over unreduced protein and indicates that His-PLO CON is subject to oxygen inactivation.
Thiol-activation of His-PLO.C 492
The two members of the CDC family that are not subject to thiol-activation, PLO and ILY, each have divergent undecapeptide sequences, which include substitution of the conserved cysteine residue with an alanine residue (Billington et al., 1997 ; Nagamune, 1997) . We have previously presented evidence that a His-PLO molecule in which the alanine residue has been changed to the conserved cysteine residue (His-PLO.C %*# ) is not subject to oxygen inactivation (Billington et al., 1997) (Fig. 1b) . However, our results that the activity of His-PLO CON can be activated by reducing agents led us to re-examine the activity of His-PLO.C %*# . Our initial experiments were performed on freshly prepared His-PLO and His-PLO.C %*# (Billington et al., 1997) . However, haemolytic assays performed on purified His-PLO.C %*# following its storage for a 2-week period at 4 mC indicated that the haemolytic activity of this protein had been reduced to only 4n9 % of wild-type His-PLO. This activity could be restored by pretreatment with either BME or DTT to 44n2 and 34n7% of His-PLO activity, respectively (Table 3) , which approximates the activity originally observed with freshly purified His-PLO.C %*# (Billington et al., 1997) . There-fore, contrary to our previous results (Billington et al., 1997) , PLO can be engineered to be thiol-activated by the introduction of the conserved cysteine residue into the undecapeptide but, even when activated, this mutant is not as active as wild-type His-PLO.
Cholesterol-binding activities of His-PLO mutant proteins
Cholesterol is the major host-cell-surface receptor for CDCs and the undecapeptide region of these toxins has been implicated either in direct binding of cholesterol or in membrane insertion as a result of cholesterol binding. Each of the His-PLO mutant proteins was compared with His-PLO for its ability to bind to cholesterol in an ELISA-based assay. The ability of all mutant toxins, with the exception of His-PLO.C %*# , to bind cholesterol was in direct proportion to the haemolytic activity of the toxin (Tables 2 and 3 ). For example, His-PLO.ΩR &!# had a haemolytic activity of 27n5 % and a cholesterol-binding activity of 26n2 % compared to His-PLO, while His-PLO.F %*( had 0n2 and 1n6 % of His-PLO haemolytic and cholesterol-binding activities, respectively. Reduced His-PLO.C %*# , however, appeared to bind cholesterol as well as, if not better than, wild-type His-PLO (mean l 166n2 % His-PLO cholesterol-binding activity), despite having a haemolytic activity only 44n2 % that of His-PLO (Table 3) .
Membrane binding of His-PLO mutant proteins
Cholesterol is the proposed major target cell receptor for CDCs, although it is not known if initial interactions occur through other host molecules. To test the ability of the mutant toxins to bind to host-cell membranes, SRBCs incubated with each toxin were analysed by Western blotting using anti-PLO serum (Fig. 2) . Despite the variations in haemolytic activity (undetectable to 44n2 % of His-PLO) and cholesterol binding (undetectable to 166n2 % of His-PLO), all mutant toxins bound to SRBC membranes, and no obvious defects in binding compared to His-PLO could be determined from this assay.
DISCUSSION
The undecapeptide of CDCs has for some time been implicated in the cytolytic activity of these toxins. This region is the largest stretch of identity among the toxins that originally formed the thiol-activated cytolysin family. However, with the discovery of the variant undecapeptide sequences of PLO (Billington et al., 1997) and ILY (Nagamune, 1997) , the requirement for identity within this undecapeptide region to produce a functional cytolysin has been questioned (Billington et al., 2000) . The haemolytic activity of PLO against SRBCs is approximately 10 % that of PFO (S. J. Billington, unpublished observation), so it is possible that the variant undecapeptide of PLO is responsible for this reduced activity. However, PLO is the most divergent member of the CDC family (Billington et al., 1997) , and it is also possible that the variations in the PLO undecapeptide sequence are required to compensate for structural differences imposed on the undecapeptide by other regions of the molecule. To assess the requirement for its variant undecapeptide, we have introduced various mutations into the undecapeptide of His-PLO. All mutations introduced had a deleterious effect on the cytolytic activity of His-PLO. In particular, the introduction of a consensus undecapeptide resulted in very low haemolytic activity, indicating that the variant undecapeptide of PLO is required for its full cytolytic activity.
Of the changes in the undecapeptide sequence of PLO compared to the CDC consensus, the proline insertion appears to have the greatest effect, since removal of this amino acid resulted in a protein that was non-haemolytic, even at very high toxin concentrations. The importance of P %** may be to provide the correct spacing between important residues, such as the three undecapeptide tryptophan residues. However, the substitution of P %** with either the similarly bulky amino acid phenylalanine or the flexible amino acid glycine did not result in functional proteins, suggesting that spacing alone does not explain the importance of P %** . Proline residues are important in the structural integrity of many proteins, as they can force peptide bends. In fact, the general conservation of proline residues within CDC primary sequences suggests that they may be involved in the maintenance of higher-order structures (Billington et al., 1997) . The undecapeptide proline residue may be required to align the PLO undecapeptide to compensate for structural differences imposed on the PLO undecapeptide by other regions of the PLO molecule, which vary considerably in primary amino acid sequence from the structural backbone of other CDCs. Interestingly, ILY, which is not nearly as divergent in its primary sequence, also contains a proline at the same position in the undecapeptide as PLO ( Fig. 1a ; Nagamune, 1997) . However, in ILY the terminal arginine is retained and the third tryptophan residue is missing, which may have implications for its binding to host cells. Indeed, ILY appears to show more specificity in host-cell type than other members of the CDC family (Nagamune, 1997 ; Nagamune et al., 1996) . Despite the differences in the PLO undecapeptide, it shares the three hydrophobic tryptophan residues which have been demonstrated to play a pivotal role in the cytolytic activity of many CDCs (Boulnois et al., 1991 ; Korchev et al., 1998 ; Michel et al., 1990 ; Nakamura et al., 1998 ; Sekino-Suzuki et al., 1996) . However, the spacing between the first and second tryptophan is altered by insertion of P %** . Mutations in each of the tryptophan residues resulted in vastly reduced cytolytic activity in LLO, PFO and PLY (Boulnois et al., 1991 ; Korchev et al., 1998 ; Michel et al., 1990 ; Sekino-Suzuki et al., 1996) . Consistent with results from other CDCs, substitution of any of the tryptophan residues of PLO with phenylalanine resulted in a substantial reduction in haemolytic activity compared to the wild-type, suggesting that the undecapeptide plays a similar role in PLO as it does in other members of the family. The role of the undecapeptide sequence in the initial binding, tethering or membrane sampling of CDCs has yet to be proven. However, the position of the first undecapeptide tryptophan residue at the very tip of the undecapeptide loop (Rossjohn et al., 1997) implies a prominent role in any initial interaction with the target cell membrane precipitated by domain 4. The marked effect of mutations at this position in PLO (Table 2 ) and other CDCs (Boulnois et al., 1991 ; Sekino-Suzuki et al., 1996) supports the importance of this residue in CDC cytolytic activity.
Contrary to results with PFO (Sekino-Suzuki et al., 1996 ; Shimada et al., 1999) , mutations in undecapeptide amino acids of His-PLO that resulted in decreased cytolytic activity, with the exception of the alanine to cysteine change in His-PLO.C %*# , also resulted in a concomitant reduction in cholesterol binding. There are several possible explanations for this observation. The undecapeptide of PLO may be intimately involved in cholesterol binding or mutations in undecapeptide residues may directly affect the cholesterol-binding site of PLO. Alternatively, mutations in the PLO undecapeptide may have a considerable effect on the structure of the PLO molecule, in particular domain 4, which likely contains the cholesterol-binding domain, such that it can no longer bind cholesterol. The variant nature of the PLO undecapeptide may be required not only to properly align the undecapeptide sequence but also to maintain the structure of domain 4 in general. Support for the latter comes from minor substitutions at the C terminus of CDCs (Owen et al., 1994 ; Shimada et al., 1999) , which disrupt the ability of these toxins to bind to cholesterol and host-cell membranes. Aligned with this final suggestion is the possibility that mutations introduced in this study result in the misfolding of domain 4, or indeed the entire PLO protein structure, leading to the reduction in haemolytic and cholesterolbinding activities. This is not the case with the majority of mutations in this region of PFO (Sekino-Suzuki et al., 1996) , where reduction in haemolytic activity was observed in the absence of major structural changes. Despite the reduced ability to bind to cholesterol, each of the His-PLO mutant toxins was still able to bind to erythrocyte membranes. These results suggest that CDCs may also bind through additional host-cell molecules (Dubail et al., 2001 ; Owen et al., 1994) . This suggestion is supported by experiments with a truncated LLO molecule composed of domains 1, 2 and 3 but lacking the cholesterol-binding domain 4, which indicated that this truncated molecule could still bind to host-cell membranes (Dubail et al., 2001 ).
The thiol-activated nature of the original members of the CDC family is the result of oxidation of the cysteine residue at position 2 of the undecapeptide motif (Michel et al., 1990 ; Pinkney et al., 1989 ; Saunders et al., 1989) . Generally, mutagenesis of this cysteine residue to alanine resulted in a toxin with a similar cytolytic activity, but which was not inactivated by oxygen (Michel et al., 1990 ; Pinkney et al., 1989 ; Saunders et al., 1989) . The identification of PLO and ILY confirmed speculation by Pinkney et al. (1989) as to the presence of members of the CDC family that lack the cysteine residue and thus would be able to stably express their cytolytic activity. The significance of the thiol-activation of CDCs is unknown. It may be a fortuitous event in evolution, but the simplicity of the substitution to an oxygen-resistant form suggests some selection for the oxygen-sensitive form. It is possible that oxygen sensitivity may regulate toxin function following secretion by pathogenic bacteria in the host, although expression of an oxygenstable form of LLO had no effect on the pathogenesis of Listeria monocytogenes in mice (Michel et al., 1990) . The His-PLO.C %*# toxin, while reduced for haemolytic activity, appeared to bind cholesterol better than wildtype His-PLO. Perhaps in a molecule more amenable to its presence, the cysteine aids in the interaction of domain 4 with the primary host-cell receptor. Anecdotally, the His-PLO.C %*# protein loses activity much more slowly than His-PLO CON , although both lose approximately 90 % of activity to oxygen inactivation. This observation may support the initial assertion that the variant sequence of the PLO undecapeptide affects the stability of PLO to oxygen, even in the presence of the cysteine substitution (Billington et al., 1997) . We conclude that the variant undecapeptide of PLO is required for full cytolytic activity of this toxin. It seems likely that the altered residues in the PLO undecapeptide may compensate for structural changes in other parts of PLO, with respect to other CDCs, as PLO has the most divergent amino acid sequence (Billington et al., 1997) . It is also possible that the undecapeptide controls hostcell-membrane sampling. PLO is known to more-readily lyse erythrocytes from some animals species (e.g. rabbit or sheep) than other species (e.g. bovine) (Funk et al., 1996) . This suggestion has implications for the variant undecapeptide of ILY and its limited host range (Nagamune, 1997 ; Nagamune et al., 1996) .
